Proposal of M/s. Mylan Laboratories Limited for increase in FDI up to US $ 750 million in MLL by Mylan Luxembourg S.a.r.l. Luxembourg and / or Mylan Group B.V. Netherlands through subscription of equity shares and / or compulsorily convertible debentures for providing MLL part of the funds required for the acquisition of the entire shareholding of JPL post the demerger from its then shareholders

Proposal of M/s. Mylan Laboratories Limited for increase in FDI up to US $ 750 million in MLL by Mylan Luxembourg S.a.r.l. Luxembourg and / or Mylan Group B.V. Netherlands through subscription of equity shares and / or compulsorily convertible debentures for providing MLL part of the funds required for the acquisition of the entire shareholding of JPL post the demerger from its then shareholders https://www.taxtmi.com/news?id=15161 Approval for foreign investment is conditional on maintaining pre investment production levels of consumables and NLEM medicines and maintaining R&D expenditure at the highest prior three year level for five years; benchmarks are set by the highest of the three preceding financial years. Full information on any transfer of technology must be provided; no non compete may be imposed on the prospective investor; subsequent related acquisitions and all tax consequences, including capital gains, dividends, interest, treaty relief, anti avoidance applicability and valuation, will be independently examined by tax authorities and do not receive immunity from investigation. en-us Fri, 06 Nov 2015 09:29:27 +0530 Fri, 06 Nov 2015 09:29:27 +0530 TaxTMI RSS Generator Proposal of M/s. Mylan Laboratories Limited for increase in FDI up to US $ 750 million in MLL by Mylan Luxembourg S.a.r.l. Luxembourg and / or Mylan Group B.V. Netherlands through subscription of equity shares and / or compulsorily convertible debentures for providing MLL part of the funds required for the acquisition of the entire shareholding of JPL post the demerger from its then shareholders https://www.taxtmi.com/news?id=15161 Approval for foreign investment is conditional on maintaining pre investment production levels of consumables and NLEM medicines and maintaining R&D expenditure at the highest prior three year level for five years; benchmarks are set by the highest of the three preceding financial years. Full information on any transfer of technology must be provided; no non compete may be imposed on the prospective investor; subsequent related acquisitions and all tax consequences, including capital gains, dividends, interest, treaty relief, anti avoidance applicability and valuation, will be independently examined by tax authorities and do not receive immunity from investigation. News - Fri, 06 Nov 2015 09:29:27 +0530 https://www.taxtmi.com/news?id=15161